Billam PLC
30 March 2007
Billam plc (the 'Company')
Revision to compromise agreement
Billam plc announced at its Annual General Meeting held on 14 July 2006 that
agreement had been reached with the Company's creditor and former Chief
Executive, Angus Forrest to settle the outstanding balance owed to him in cash
over a two year period.
A further agreement has now been reached by which Billam will make an early
payment to Mr Forrest and in return he will receive the Company's shareholdings
in TMO Biotech Limited ('TMO'), Intellego Holdings plc and the balance being
made up of shares in Cybit Holdings plc for a total consideration of £215,000.
The holding in TMO is being sold at a profit of £36,426 and the two quoted
holdings are being sold at the bid and mid market price respectively.
The outstanding total sum of £177,456.30 will be paid to Mr Forrest in three,
equal installments, commencing on 30 September 2007 and ending on 30 September
2008.
Enquiries:
Simon Bennett Tel: +44 (0) 20 7222 1918
Chairman
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.